Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization
NCT ID: NCT04869735
Last Updated: 2021-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2125 participants
OBSERVATIONAL
2021-06-04
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In France, the vaccination schedule sets the vaccination recommendations applicable to people according to their age. In this schedule, a booster of DTPolio at the age of 25 is recommended.
The vaccination coverage for patients over 16 years of age is insufficient in France.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants
NCT02477995
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
NCT05951725
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
NCT00447525
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
NCT01546909
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
NCT01323959
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With information about booster vaccination
Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
Data collection: DTPolio vaccine delivery
"with information about booster vaccination" group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS "without information about booster vaccination" group: no intervention
Without information about booster vaccination
Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
Data collection: DTPolio vaccine delivery
"with information about booster vaccination" group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS "without information about booster vaccination" group: no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection: DTPolio vaccine delivery
"with information about booster vaccination" group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS "without information about booster vaccination" group: no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* without delivery of DTPolio vaccine in 2019 or 2020
Exclusion Criteria
25 Years
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Reims Champagne-Ardenne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brigitte VUILLEMIN
Role: PRINCIPAL_INVESTIGATOR
Université de Reims CHampahne-Ardenne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Université de Reims Champagne-Ardenne
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-003-Info-Vac
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.